English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/36617
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:
Title

Chaperone Activity of Bicyclic Nojirimycin Analogues for Gaucher Mutations in Comparison with N-(n-nonyl)Deoxynojirimycin

AuthorsLuan, Zhuo; Higaki, Katsumi; Aguilar Moncayo, Matilde ; Ninomiya, Haruaki; Ohno, Kousaku; García Moreno, María Isabel; Ortiz-Mellet, Carmen; García-Fernández, José Manuel; Suzuki, Yoshiyuki
KeywordsGaucher disease
Glucocerebrosidase
Glucosidase
Imino sugars
Inhibitors
Medicinal chemistry
Issue Date14-Oct-2009
PublisherWiley-VCH
CitationChemBioChem 10(17): 2780-2792 (2009)
AbstractGaucher disease (GD), the most prevalent lysosomal storage disorder, is caused by mutations of lysosomal β-glucosidase (acid β-Glu, β-glucocerebrosidase); these mutations result in protein misfolding. Some inhibitors of this enzyme, such as the iminosugar glucomimetic N-(n-nonyl)-1-deoxynojirimycin (NN-DNJ), are known to bind to the active site and stabilize the proper folding for the catalytic form, acting as “chemical chaperones” that facilitate transport and maturation of acid β-Glu. Recently, bicyclic nojirimycin (NJ) analogues with structure of sp2 iminosugars were found to behave as very selective, competitive inhibitors of the lysosomal β-Glu. We have now evaluated the glycosidase inhibitory profile of a series of six compounds within this family, namely 5-N,6-O-(N′-octyliminomethylidene-NJ (NOI-NJ), the 6-thio and 6-amino-6-deoxy derivatives (6S-NOI-NJ and 6N-NOI-NJ) and the corresponding galactonojirimycin (GNJ) counterparts (NOI-GNJ, 6S-NOI-GNJ and 6N-NOI-GNJ), against commercial as well as lysosomal glycosidases. The chaperone effects of four selected candidates (NOI-NJ, 6S-NOI-NJ, 6N-NOI-NJ, and 6S-NOI-GNJ) were further evaluated in GD fibroblasts with various acid β-Glu mutations. The compounds showed enzyme enhancement on human fibroblasts with N188S, G202R, F213I or N370S mutations. The chaperone effects of the sp2 iminosugar were generally stronger than those observed for NN-DNJ; this suggests that these compounds are promising candidates for clinical treatment of GD patients with a broad range of β-Glu mutations, especially for neuronopathic forms of Gaucher disease.
Description13 páginas, 2 figuras, 3 tablas, 4 esquemas
Publisher version (URL)http://dx.doi.org/10.1002/cbic.200900442
URIhttp://hdl.handle.net/10261/36617
DOI10.1002/cbic.200900442
ISSN1429-4227
E-ISSN1439-7633
Appears in Collections:(IIQ) Artículos
Files in This Item:
There are no files associated with this item.
Show full item record
Review this work
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.